IL2 and cancer: Immune responses to a self- antigen are different from those to a foreign antigen; therefore our findings in the MUC1 mouse model cannot predict whether MVA- MUC1-IL-2 vaccine is a good candidate for therapeutic combination with radiation in cancer patients.